HCW Biologics (NASDAQ:HCWB – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($2.83) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($1.48), FiscalAI reports. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.12 million. HCW Biologics had a negative return on equity of 262.33% and a negative net margin of 83.03%.
HCW Biologics Price Performance
HCWB opened at $0.86 on Tuesday. HCW Biologics has a one year low of $0.74 and a one year high of $23.94. The company’s 50 day simple moving average is $1.48 and its 200-day simple moving average is $3.79. The stock has a market capitalization of $1.94 million, a P/E ratio of -0.03 and a beta of 2.31.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, October 15th. Wall Street Zen raised HCW Biologics from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $30.00.
Check Out Our Latest Analysis on HCWB
HCW Biologics Company Profile
HCW Biologics is a clinical-stage biopharmaceutical company developing immunotherapies designed to address chronic inflammation, which the company views as a contributor to aging and age-related diseases. Its research also includes potential treatments for cancer and other serious conditions. The company uses proprietary biologics platforms to discover and develop engineered therapeutic candidates. Its pipeline includes investigational fusion-protein therapies intended to modulate immune activity; these candidates remain under clinical development and are not approved for commercial use.
Recommended Stories
- Five stocks we like better than HCW Biologics
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
